Continuous glucose monitoring in youth with cystic fibrosis treated with lumacaftor-ivacaftor
Angel Li, Tim Vigers, Laura Pyle, Edith Zemanick, Kristen Nadeau, Scott D Sagel, Christine L Chan, Angel Li, Tim Vigers, Laura Pyle, Edith Zemanick, Kristen Nadeau, Scott D Sagel, Christine L Chan
Abstract
Background: The effects of lumacaftor-ivacaftor therapy on glycemia have not been thoroughly investigated. Continuous glucose monitoring (CGM) provides detailed information about glycemic patterns and detects glucose abnormalities earlier than traditional screening tools for diabetes.
Methods: CGM measures, HbA1c, and oral glucose tolerance test (OGTT) results were collected and within-subject results compared in F508del homozygous youth with CF before and after initiation of lumacaftor-ivacaftor using the Wilcoxon signed-rank test.
Results: Nine youth with CF (6 males, median age 12.7 years) were enrolled. CGM was performed in all participants before (median 26 weeks) and after lumacaftor-ivacaftor (median 29 weeks). HbA1c and fasting plasma glucose increased (p = .02) after lumacaftor-ivacaftor initiation. No changes in OGTT 1 h or 2 h glucose nor CGM measures were observed overall. When analyzed by sex, males showed lower glycemic variability, as reflected by the mean amplitude of glycemic excursions, on the post-treatment CGM.
Conclusions: Glycemic abnormalities persisted in CF patients treated with lumacaftor-ivacaftor, although sex-dependent differences in glycemic response to treatment may exist.
Keywords: Continuous glucose monitoring; Cystic fibrosis related diabetes; Cystic fibrosis transmembrane conductance regulator protein modulator.
Conflict of interest statement
Conflict of interest statement: The authors have no conflicts of interest to disclose.
Copyright © 2018 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
Source: PubMed